Trial Profile

A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use

Most Recent Events

02 Aug 2024 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
02 Aug 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
01 Oct 2022 Results (n=14)by obtaining blood samples from NCT02756897; elucidating the proteomic landscape during therapy, published in the Clinical Lymphoma, Myeloma & Leukemia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com